filmarray
respiratori
panel
rp
biofir
diagnost
inc
salt
lake
citi
ut
usa
first
multiplex
molecular
panel
clear
us
fda
detect
bacteri
viral
respiratori
pathogen
nasopharyg
swab
filmarray
rp
target
pathogen
includ
virus
subtyp
three
bacteria
perform
minim
sampl
manipul
filmarray
rp
fulli
autom
sampletoansw
workflow
turnaroundtim
approxim
h
report
sensit
specif
assay
rang
respect
sensit
adenoviru
low
new
version
filmarray
rp
assay
version
improv
sensit
adenoviru
releas
perform
characterist
simplifi
workflow
allow
implement
wide
rang
laboratori
filmarray
rp
chang
diagnost
landscap
signific
impact
care
patient
respiratori
tract
infect
filmarray
respiratori
panel
rp
biofir
diagnost
inc
salt
lake
citi
ut
usa
first
multiplex
molecular
panel
clear
us
fda
detect
bacteri
viral
respiratori
pathogen
nasopharyg
swab
filmarray
rp
target
pathogen
includ
virus
subtyp
three
bacteria
perform
minim
sampl
manipul
filmarray
rp
fulli
autom
sampletoansw
workflow
turnaroundtim
approxim
h
report
sensit
specif
assay
rang
respect
sensit
adenoviru
low
new
version
filmarray
rp
assay
version
improv
sensit
adenoviru
releas
perform
characterist
simplifi
workflow
allow
implement
wide
rang
laboratori
filmarray
rp
chang
diagnost
landscap
signific
impact
care
patient
respiratori
tract
infect
communityacquir
respiratori
tract
infect
occur
vari
frequenc
throughout
year
infect
among
common
reason
healthcar
visit
caus
viral
bacteri
pathogen
symptom
caus
virus
nonspecif
includ
sore
throat
runni
nose
wateri
eye
cough
wheez
short
breath
sputum
product
nasal
congest
addit
symptom
indistinguish
caus
bacteri
pathogen
mix
infect
two
respiratori
pathogen
uncommon
might
underreport
due
limit
sensit
method
current
use
diagnosi
ident
pathogen
caus
symptom
critic
rapid
institut
adequ
antivir
antibiot
therapi
well
proper
isol
infect
patient
prevent
healthcar
associ
infect
devast
effect
immunocompromis
popul
empir
broadspectrum
therapi
often
administ
due
limit
convent
diagnost
method
provid
time
result
guid
clinician
decis
great
illustr
import
specif
diagnosi
came
emerg
novel
influenza
viru
unlik
season
influenza
viru
novel
viru
sensit
antivir
drug
oseltamivir
tamiflu
resist
amantadin
rimantadin
symadin
flumadin
sinc
respiratori
symptom
two
influenza
virus
similar
accur
time
identif
correct
viru
critic
administr
appropri
therapi
normal
host
respiratori
viral
infect
selflimit
although
complic
occur
last
two
decad
respiratori
virus
becom
increasingli
recogn
seriou
caus
morbid
mortal
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
sot
recipi
part
treatment
patient
undergo
hsct
sot
becom
sever
immunosuppress
render
highli
suscept
infecti
pathogen
seriou
complic
fatal
includ
viral
pneumonia
later
airflow
obstruct
syndrom
graft
reject
superinfect
bacteri
fungal
pathogen
similarli
respiratori
virus
signific
impact
young
children
elderli
patient
result
frequent
hospit
signific
health
cost
common
virus
caus
respiratori
ill
includ
influenza
viru
type
influenza
viru
type
b
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
human
metapneumoviru
hmpv
picornavirus
rhinovirus
enterovirus
children
undergo
treatment
hematolog
malign
infect
due
influenza
parainfluenza
parainfluenza
virus
rsv
particularli
common
signific
impact
oncolog
care
clinic
signific
virus
bocaviru
human
coronavirus
human
coronavirus
parainfluenza
viru
rhinoviru
less
clear
respiratori
tract
infect
caus
bacteri
pathogen
includ
streptococcu
pneumonia
haemophilu
influenza
well
atyp
bacteri
often
difficult
cultur
laboratori
includ
chlamydophila
pneumonia
mycoplasma
pneumonia
influenza
virus
envelop
neg
sens
singlestrand
rna
ssrna
virus
belong
orthomyxovirida
famili
three
type
influenza
virus
influenza
viru
type
influenza
viru
type
b
influenza
viru
type
c
type
b
commonli
isol
type
c
rare
often
includ
routin
diagnost
test
influenza
virus
type
subtyp
base
sequenc
two
glycoprotein
hemagglutinin
h
neuraminidas
n
influenza
virus
caus
annual
season
epidem
character
increas
frequenc
upper
respiratori
symptom
seen
commun
decemb
may
northern
hemispher
although
infect
usual
remain
limit
upper
respiratori
tract
patient
complic
due
influenza
virus
report
hsct
sot
patient
especi
lung
transplant
recipi
one
studi
frequenc
pneumonia
caus
influenza
virus
fatal
rate
hsct
recipi
howev
report
frequenc
complic
vari
fatal
rang
hsct
recipi
sot
complic
rate
vari
base
organ
transplant
lung
transplant
recipi
particularli
increas
risk
rsv
envelop
nonseg
ssrna
viru
belong
paramyxovirida
famili
season
rsv
follow
close
influenza
virus
increas
incid
winter
month
northern
hemispher
transplant
patient
young
children
infect
rsv
result
seriou
complic
center
detect
rsv
pretranspl
result
delay
sct
patient
clear
infect
one
studi
hsct
recipi
patient
upper
respiratori
rsv
infect
develop
pneumonia
exhibit
symptom
within
day
follow
upper
respiratori
tract
symptom
larg
studi
children
year
age
incid
rsv
infect
rsv
infect
occur
previous
healthi
children
preexist
condit
risk
factor
identifi
year
age
piv
nonseg
neg
sens
rna
virus
structur
relat
rsv
belong
paraxmyxovirida
famili
four
predomin
piv
serotyp
includ
recent
rare
isol
sinc
diagnost
assay
avail
includ
reagent
detect
less
inform
avail
piv
subtyp
northern
hemispher
piv
occur
yearround
occur
frequent
fall
occur
fall
earli
winter
occur
spring
summer
month
infect
caus
piv
usual
mild
rang
asymptomat
shed
common
cold
croup
bronchiol
similar
rsv
piv
infect
occur
frequent
children
children
expos
age
two
age
report
incid
piv
hstc
popul
rang
progress
lower
respiratori
tract
infect
lrti
lrti
result
death
infect
caus
lung
transplant
recipi
piv
lrti
associ
high
rate
allograft
reject
hmpv
hmpv
anoth
member
paraxmyxovirida
famili
structur
relat
rsv
piv
rel
newli
describ
viru
becom
increasingli
recogn
caus
signific
respiratori
ill
young
children
older
adult
immunocompromis
patient
incid
hmpv
hsct
patient
rang
complic
fatal
rate
similar
rsv
similar
paramyxovirida
virus
hmpv
result
graft
dysfunct
andor
reject
lung
transplant
recipi
adenovirus
nonenvelop
doubl
strand
dna
virus
belong
adenovirida
famili
adenovirus
divid
seven
type
ag
serotyp
type
bc
commonli
associ
respiratori
ill
adenovirus
remain
dormant
lymphoid
cell
may
reactiv
follow
immunosuppress
adenovirus
present
yearround
common
pediatr
popul
gener
caus
selflimit
mild
infect
incid
adenoviru
hsct
sot
patient
rang
respect
vari
patient
age
type
transplant
degre
immunosuppress
organ
transplant
rhinovirus
small
ssrna
virus
picornavirida
famili
rhinovirus
divers
group
virus
serotyp
identifi
date
rhinovirus
common
caus
common
cold
isol
throughout
year
peak
incid
septemb
healthi
individu
rhinoviru
infect
usual
selflimit
symptom
last
day
sever
report
link
rhinovirus
sever
present
includ
otiti
media
bronchiol
exacerb
asthma
children
immunocompromis
host
sever
complic
includ
pneumonia
occur
one
recent
studi
sever
rhinoviru
infect
immunocompromis
patient
similar
pandem
influenza
use
current
diagnost
molecular
method
inform
frequenc
sever
infect
caus
rhinovirus
becom
avail
coronavirus
cov
largest
rna
virus
belong
coronavirida
famili
along
torovirus
cov
divid
three
group
base
sequenc
homolog
group
includ
group
includ
group
includ
human
cov
cov
respons
wide
rang
upper
respiratori
tract
infect
urti
associ
mainli
common
cold
limit
number
report
cov
infect
immunocompromis
host
avail
one
studi
asymptomat
shed
cov
detect
first
day
follow
allogen
hsct
report
lirt
fatal
outcom
report
patient
follow
sct
bacteri
pathogen
includ
respiratori
panel
rp
includ
bordetella
pertussi
mycoplasma
pneumonia
chlamydophila
pneumonia
three
organ
caus
upper
lower
respiratori
tract
infect
includ
acut
sinus
bronchiti
pneumonia
b
pertussi
caus
pertussi
whoop
cough
primarili
nonvaccin
children
adult
infect
associ
persist
cough
week
atyp
organ
includ
pneumonia
c
pneumonia
account
one
third
case
bacteri
pneumonia
unlik
common
bacteria
associ
symptom
b
pertussi
pneumonia
c
pneumonia
grow
readili
media
use
routin
bacteri
cultur
therefor
requir
high
level
suspicion
clinician
inform
laboratori
request
specif
diagnost
test
one
studi
persist
cough
least
week
observ
children
infect
one
three
organ
underscor
need
sensit
specif
diagnosi
guid
therapi
diagnost
assay
respiratori
pathogen
convent
method
use
diagnos
respiratori
viral
infect
includ
rapid
antigen
test
direct
fluoresc
antibodi
assay
shell
vial
viral
cultur
method
advantag
disadvantag
sensit
specif
rang
respect
requir
addit
test
neg
specimen
addit
assay
subject
requir
expertis
interpret
cytopath
effect
limit
rang
detect
turnaroundtim
long
day
molecular
assay
base
pcr
rapid
sensit
compar
convent
method
recent
individu
laboratori
appropri
expertis
develop
implement
realtim
pcr
assay
common
respiratori
virus
sever
commerci
assay
researchus
ruo
clear
fda
tabl
wide
avail
facilit
implement
technolog
diagnost
microbiolog
laboratori
recent
fdaapprov
molecular
assay
target
commonli
isol
virus
includ
influenza
b
virus
rsv
either
singleplex
duplex
assay
although
method
benefit
target
approach
diagnosi
respiratori
infect
limit
common
virus
requir
clinician
order
multipl
test
alway
permit
detect
coinfect
pathogen
altern
approach
develop
broadli
multiplex
assay
allow
simultan
detect
wider
rang
possibl
pathogen
greater
one
singl
tube
fda
clear
first
broadli
multiplex
molecular
assay
xtag
respiratori
viral
panel
two
studi
evalu
perform
esensor
rvp
compar
multiplex
respiratori
panel
includ
filmarray
rp
xtag
rvp
xtag
rvp
fast
laboratori
develop
test
sensit
specif
esensor
rvp
vari
depend
viral
target
filmarray
rp
assay
first
fdaclear
assay
qualit
detect
nucleic
acid
target
virus
bacteria
nasopharyng
swab
specimen
filmarray
rp
initi
fdaclear
detect
virus
includ
virus
xtag
rvp
plu
cov
five
target
clear
includ
cov
three
bacteri
target
b
pertussi
c
pneumonia
pneumonia
version
increas
detect
rate
adenoviru
second
assay
viru
ad
rp
fda
clear
version
assay
perform
filmarray
instrument
complet
approxim
h
filmarray
integr
platform
combin
autom
sampl
prepar
total
nucleic
acid
extract
nest
multiplex
pcr
revers
transcriptas
pcr
autom
detect
amplifi
target
instrument
small
footprint
cm
contain
pneumat
electr
compon
move
reagent
pouch
perform
function
describ
nest
pcr
effect
use
two
peltier
devic
melt
curv
detect
use
blue
led
light
sourc
charg
coupl
devic
ccd
camera
figur
nucleic
acid
releas
cell
combin
action
denatur
buffer
ceram
bead
bead
beater
lyse
cell
transfer
blister
contain
magnet
bead
bind
releas
nucleic
acid
follow
applic
magnet
sever
wash
nucleic
acid
elut
move
pcr
site
amplif
purifi
dnarna
extract
mix
first
stage
multiplex
pcr
reagent
includ
set
outer
primer
temperatur
cycl
occur
first
peltier
devic
revers
transcript
pcr
step
perform
prior
first
pcr
cycl
amplif
target
nucleic
acid
accomplish
use
principl
nest
pcr
use
two
stage
approach
increas
sensit
specif
pcr
reaction
result
mixtur
dilut
move
second
stage
pcr
amplifi
product
first
stage
pcr
use
templat
amplifi
use
second
set
inner
primer
cycl
occur
second
peltier
devic
second
stage
pcr
lcgreen
plu
fluoresc
dna
intercal
dye
incorpor
dna
amplifi
posit
reaction
determin
base
dna
melt
curv
analysi
amplifi
product
target
run
triplic
three
separ
well
microarray
melt
curv
individu
replic
target
measur
follow
amplif
posit
reaction
determin
melt
curv
shape
peak
fall
within
preestablish
rang
control
instrument
interpret
result
done
automat
filmarray
softwar
reproduc
permiss
biofir
diagnost
filmarray
rp
diagnost
profil
wwwexpertreviewscom
pouch
reagent
necessari
perform
assay
contain
vacuum
seal
filmarray
pouch
lyophil
reagent
distribut
separ
reservoir
rehydr
buffer
solut
prior
ad
specimen
addit
reagent
contain
three
pouch
six
blister
includ
ceram
bead
lysi
magnet
bead
dna
rna
purif
oligonucleotid
first
stage
pcr
blister
connect
channel
use
move
liquid
reaction
one
blister
anoth
last
section
pouch
solidphas
array
set
well
well
contain
primer
second
stage
pcr
figur
filmarray
rp
target
virus
bacteria
includ
influenza
viru
type
includ
subtyp
influenza
viru
type
b
rsv
adenoviru
hmpv
rhinovirusesenterovirus
cov
b
pertussi
c
pneumonia
pneumonia
addit
assay
contain
two
target
control
rna
target
schizosaccharomyc
pomb
control
entir
process
extract
dna
melt
analysi
dna
target
control
includ
array
well
control
second
stage
pcr
target
least
three
replic
assay
final
interpret
determin
number
replic
posit
filmarray
rp
multipl
target
pathogen
detect
eg
influenza
viru
type
two
paninfluenza
target
one
ha
specif
target
publish
report
perform
filmarray
rp
summar
tabl
filmarray
rp
evalu
fda
clear
molecular
assay
publish
report
evalu
premarket
version
filmarray
rp
sampl
pediatr
patient
preval
respiratori
virus
expect
higher
overal
filmarray
rp
sensit
specif
howev
report
sensit
first
version
filmarray
rp
adenoviru
around
note
manufactur
releas
new
version
filmarray
rp
improv
adenoviru
detect
rand
et
al
compar
perform
filmarray
rp
xtag
rvp
specimen
adult
pediatr
patient
previous
test
viral
cultur
antigen
test
complet
agreement
two
test
excel
virus
detect
filmarray
rp
virus
filmarray
rp
versu
virus
xtag
rvp
notabl
filmarray
rp
greater
sensit
rsv
xtag
rvp
vs
loeffelholz
colleagu
compar
filmarray
rp
seri
fda
clear
prodess
genprob
realtim
pcr
assay
includ
proflu
profast
proparaflu
prohmpv
proadeno
filmarray
rp
prodess
assay
show
good
overal
agreement
test
specimen
pediatr
patient
filmarray
rp
sensit
detect
addit
two
three
detect
proparaflu
assay
proadeno
sensit
adenovirus
filmarray
rp
detect
total
adenovirus
compar
five
adenoviru
detect
filmarray
rp
addit
author
compar
filmarray
rp
ldt
target
includ
prodess
assay
sensit
rang
although
number
posit
specimen
test
small
n
except
rhinovirusenteroviru
n
target
compar
perform
filmarray
rp
premarket
version
xtag
rvp
fast
respiratori
specimen
pediatr
patient
report
filmarray
rp
overal
sensit
xtag
rvp
fast
virus
common
assay
especi
rsv
vs
flub
vs
howev
xtag
rvp
fast
sensit
filmarray
rp
vs
rhinovirus
vs
recent
studi
filmarray
rp
evalu
along
multiplex
fdaclear
molecular
assay
includ
xtag
rvp
xtag
rvp
fast
genmark
esensor
filmarray
rp
overal
sensit
sensit
vari
influenza
viru
mpv
rsv
b
sensit
vari
influenza
viru
influenza
viru
rsv
rhinovirusesenterovirus
note
sensit
filmarray
rp
xtag
rvp
rsv
similar
sensit
filmarray
rp
adenovirus
especi
low
report
studi
studi
evalu
filmarray
rp
convent
method
laboratorydevelop
assay
ruo
assay
one
studi
done
use
mock
specimen
prepar
combin
previous
posit
nasal
wash
nasal
swab
bronchoalveolar
lavag
fluid
sputum
tracheal
aspir
filmarray
rp
detect
virus
identifi
ldt
assay
discord
result
mainli
occur
low
viral
load
filmarray
rp
also
evalu
resplex
ii
panel
qiagen
two
test
overal
agreement
filmarray
rp
detect
posit
specimen
virus
resplex
assay
pierc
et
al
report
overal
agreement
filmarray
rp
ldt
realtim
pcr
filmarray
rp
adenoviru
assay
less
sensit
ldt
adenoviru
realtim
pcr
miss
adenoviru
posit
specimen
filmarray
rp
unabl
specif
detect
adenoviru
serotyp
viral
concentr
serotyp
low
viral
concentr
accord
manufactur
product
insert
low
sensit
filmarray
rp
adenoviru
specif
relat
adenoviru
c
serotyp
confirm
pierc
et
al
studi
recommend
test
neg
specimen
use
altern
method
detect
adenovirus
suspect
filmarray
rp
pi
april
new
version
filmarray
rp
assay
version
releas
filmarray
rp
design
enhanc
detect
adenovirus
ad
second
adenoviru
assay
panel
peerreview
publish
report
yet
avail
perform
improv
assay
adenoviru
abstract
present
clinic
virolog
symposium
show
increas
sensit
filmarray
rp
compar
filmarray
rp
vs
still
miss
adenovirus
detect
xtag
rvp
prodess
proadeno
assay
ldt
adenoviru
singleplex
respiratori
tract
infect
caus
wide
rang
pathogen
includ
virus
bacteria
addit
novel
virus
includ
bocaviru
novel
cov
increasingli
recogn
caus
respiratori
tract
ill
given
nonspecif
natur
respiratori
symptom
abil
detect
novel
virus
well
signific
pathogen
paramount
optim
patient
care
filmarray
rp
extens
panel
current
fda
clear
rapid
detect
respiratori
tract
pathogen
although
adenoviru
assay
still
requir
improv
overal
clinic
sensit
specif
filmarray
rp
assay
better
convent
method
compar
high
complex
multiplex
molecular
assay
market
multiplex
molecular
diagnost
assay
ideal
infect
wide
differenti
diagnosi
howev
design
broadli
multiplex
assay
challeng
multiplex
pcr
assay
subject
decreas
sensit
due
part
target
competit
primer
dimer
format
overal
sensit
specif
filmarray
rp
publish
report
vari
respect
sensit
adenoviru
assay
remain
challeng
even
new
version
assay
howev
even
lower
sensit
adenoviru
filmarray
rp
drastic
chang
diagnost
landscap
allow
implement
sensit
rapid
molecular
assay
wide
rang
diagnost
set
filmarray
rp
second
highli
multiplex
molecular
assay
clear
fda
first
one
includ
bacteri
pathogen
panel
import
note
howev
extens
filmarray
rp
panel
import
bacteri
caus
pneumonia
includ
pneumonia
h
influenza
includ
panel
compar
fda
clear
multiplex
assay
tabl
filmarray
rp
greatest
number
target
panel
simplest
workflow
shortest
turnaroundtim
highest
reagent
cost
true
valu
filmarray
rp
assay
lie
abil
provid
action
result
clinician
facilit
flow
patient
hospit
provid
infect
control
staff
realtim
inform
specimen
type
current
clear
fda
test
nasopharyng
swab
howev
respiratori
tract
specimen
routin
submit
laboratori
test
includ
nasal
swab
nasal
wash
throat
swab
bronchoalveolar
lavag
fluid
sputum
studi
includ
articl
evalu
offlabel
use
filmarray
rp
specimen
type
sensit
specif
similar
np
swab
suggest
rp
would
use
diagnos
upper
lower
respiratori
tract
infect
fiveyear
view
five
year
ago
fda
clear
xtag
rvp
first
broadli
multiplex
molecular
assay
detect
respiratori
virus
nasopharyng
swab
today
four
fdaclear
broadli
multiplex
assay
xtag
rvp
xtag
rvp
fast
luminex
corp
esensor
rvp
genmark
inc
filmarray
respiratori
panel
rp
biofir
diagnost
filmarray
rp
test
wide
rang
pathogen
high
sensit
specif
time
manner
filmarray
rp
rais
expect
clinic
laboratori
clinician
possibl
rapid
sensit
diagnosi
infecti
diseas
gener
next
year
see
continu
increas
option
rapid
sensit
simpl
perform
molecular
assay
infecti
diseas
diagnosi
one
limit
filmarray
rp
still
cost
compar
tradit
method
commerci
avail
molecular
diagnost
tool
although
consid
workflow
labor
cost
overal
cost
filmarray
rp
compar
highli
multiplex
assay
ie
xtag
rvp
esensor
rvp
era
health
care
reform
clinic
laboratori
hospit
constantli
face
challeng
deliv
best
patient
care
possibl
costeffect
way
filmarray
rp
fulli
realiz
potenti
cost
assay
decreas
avail
wider
rang
patient
filmarray
rp
current
classifi
moder
complex
test
subject
requir
associ
perform
moderatehigh
complex
test
includ
qualiti
control
assess
perform
test
accredit
laboratori
set
possibl
filmarray
rp
might
eventu
obtain
waiv
complex
categori
allow
use
point
care
set
like
emerg
room
doctor
offic
antivir
drug
becom
avail
treat
virus
influenza
rsv
abil
molecular
platform
rapidli
diagnos
specif
viru
respons
respiratori
syndrom
becom
even
import
furthermor
quantit
semiquantit
assay
provid
inform
viral
load
use
monitor
patient
respons
treatment
gain
better
understand
infecti
dose
virus
includ
multiplex
panel
next
five
year
see
emerg
outcom
studi
real
impact
benefit
assay
patient
care
public
health
gener
final
impact
new
emerg
infect
deni
last
year
avian
influenza
viru
middl
eastern
syndrom
coronavirus
remind
us
quickli
new
emerg
virus
appear
spread
challeng
manufactur
molecular
assay
design
assay
sensit
specif
yet
broad
enough
accommod
potenti
emerg
pathogen
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
includ
employ
consult
honoraria
stock
ownership
option
expert
testimoni
grant
patent
receiv
pend
royalti
write
assist
util
product
manuscript
respiratori
tract
infect
occur
year
long
differ
pathogen
peak
differ
time
overlap
season
distribut
clinic
symptom
caus
respiratori
pathogen
includ
bacteria
virus
nonspecif
current
four
highli
multiplex
respiratori
panel
us
fda
approv
diagnosi
respiratori
infect
filmarray
respiratori
panel
sensit
specif
simplest
workflow
fastest
turnaroundtim
assay
filmarray
respiratori
panel
panel
includ
viral
bacteri
caus
upper
respiratori
tract
infectionslow
respiratori
tract
infect
